Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. ...
Streetwise Reports | April 7, 2020 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. Early this morning, gene therapy focused biopharmaceutical company IVERIC bio Inc. (I...
Streetwise Reports | October 29, 2019 |

Is ValOre Primed for PGM’s Perfect Storm?

It has all the makings of a perfect storm of opportunity, in spite of the recent onset of a long-awaited cyclical bear market for North America’s capital markets. A surging market for platinum prices and other platinum group metals (PGMs) over the past sev...
Marc Davis | March 31, 2020 |

Two Resource Companies Moving Ahead on Many Fronts

Following the strong rally in gold and gold stocks since the March low, we expect a pullback over coming weeks. It is already underway. We do not expect it to be particularly long or deep, and will present opportunities to buy. For now, however, patience is the best cours...
Streetwise Reports | June 10, 2020 |

Rare Earth Elements Set to Take Centre Stage

When it comes to the lucrative world of mining, the long-standing stars of the show are gold and silver – particularly this year with a pandemic-driven spike in gold prices to an all-time high of more than US$2,000 per ounce. But one sector, which to date has garnered li...
Oliver Gray | December 7, 2020 |

American Lithium’s High-Octane Power Play Delights Investors

It’s a lithium power play that has created an excited buzz in Canada’s capital markets. Earlier this week, investors went on a buying frenzy after American Lithium Corp. ( TSX.V: LI , OTC: LIACF , Frankfurt: 5LA1, Forum ) stealthily swoo...
Marc Davis | February 12, 2021 |

Why Fortune Favours Chris Taylor’s Kodiak Copper

It’s a stark new reality. And investors need to listen up or lose out. Truth be told, it is no longer only the size and grade of each new mineral discovery that determines whether it can become a mine. Now, all exploration/development projects also need to ...
Marc Davis | January 24, 2022 |

PODCAST: A CBD-focused First-to-Market Franchise Model

This podcast is part of our Cannabis Sector CEO interview series. The focus of our new StockTalk Podcasts is to help listeners and investors learn about, understand, and discover investment opportunities in the public marketplace.   Stockhouse Media's Dave Jackson was r...
Dave Jackson | September 19, 2019 |
1 2 3 4 5 6 7 8 9 10 ...